News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–12
Matches
12
Sources here
5
Companies here
1
Search results Stored financial headlines

Active search

12 matching headlines

Ticker or company: BNTXNMain company stories
Clear
Latest

finance.yahoo.com Guidance

BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.

BioNTech (NASDAQ: BNTX) is entering a new chapter. The company has named Guido Oelkers, the longtime CEO of Swedish rare-disease company Sobi, as its next chief executive. Oelkers will officially take over by Feb. 1, 2027, succeeding co-founder Uğur Şahin, who helped transform BioNTech into one of the world's best-known biotechnology companies during the COVID-19 pandemic. To be …

Main company 🇲🇽 Mexico
Read at finance.yahoo.com
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

BioNTech (BNTX) Brings In New CEO As Europe Clears Updated COVID 19 Shot

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioNTech (NasdaqGS:BNTX) named Dr. Guido Oelkers as incoming CEO, marking a major leadership transition …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

seekingalpha.com Earnings Main company 🇲🇽 Mexico

BioNTech anticipates €1.6B-€1.9B 2026 revenue while advancing oncology catalysts into late 2026

Earnings Call Insights: BioNTech (BNTX) Q2 2026 MANAGEMENT VIEW * BioNTech framed its leadership transition as tied to commercialization scale, with (Chairman Helmut Jeggle) saying, "Guido Oelkers will take office as CEO as of February 1 at the latest" and highlighting that, at Sobi, …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

BioNTech Q2 Earnings Call Highlights

Key Points Interested in BioNTech SE Sponsored ADR? Here are five stocks we like better. BioNTech's Q2 revenue fell to €106 million from €261 million a year earlier due to weaker U.S. COVID-19 vaccine demand. The company lowered 2026 revenue guidance to €1.6 billion–€1.9 …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

BioNTech SE Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types Multiple …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
nasdaq.com Market update Main company 🇲🇽 Mexico

BioNTech Appoints Oelkers As CEO, Succeeding Co-Founder Sahin

(RTTNews) - BioNTech SE (BNTX) announced on Monday that its Supervisory Board has appointed Guido Oelkers to the Management Board as Chief Executive Officer (CEO), effective February 1, 2027, succeeding co-founder and CEO Ugur Sahin. Sahin is a physician and immunologist with experience in …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
nasdaq.com Regulatory and legal Main company 🇲🇽 Mexico

Pfizer-BioNTech Secures EU Marketing Authorisation For XFG-Adapted COVID-19 Vaccine

(RTTNews) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced that the European Commission (EC) has granted marketing authorisation for the COVID-19 vaccine formulation targeting the XFG variant, for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

BioNTech SE Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring

BioNTech (NASDAQ: BNTX) rose to prominence several years ago thanks to its role in the coronavirus market. The company developed Comirnaty, one of the best-selling COVID-19 vaccines, with Pfizer (NYSE: PFE). However, vaccination rates have dropped significantly due to a combination of factors, including …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
globenewswire.com Earnings Main company 🇲🇽 Mexico

BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen Fortschritt

MAINZ, Deutschland, 21. Juli 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Dienstag, den 4. August 2026, die Ergebnisse für das zweite Quartal 2026 veröffentlichen. Darüber hinaus wird das Unternehmen am selben Tag um 14:00 Uhr MEZ (8:00 …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
globenewswire.com Earnings Main company 🇲🇽 Mexico

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

MAINZ, Germany, July 21, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the Company will host a conference call and webcast that day at …

BNTXN main company
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5% BNTXN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context